# Advancements in lung and breast cancer clinical trials > Live situation record from CLSTR: https://clstr.news/situations/advancements-in-lung-and-breast-cancer-clinical-trials > Updated: 2026-09-14T06:13:00.000Z. Sources: 13. Developments: 2. Recent clinical trial data presented at the IASLC 2026 World Conference on Lung Cancer and in the Journal of Clinical Oncology highlight significant advancements in oncology treatments, particularly regarding antibody-drug conjugates (ADCs) and targeted therapies. In the treatment of non-small cell lung cancer (NSCLC), the Phase III DESTINY-Lung04 study involving trastuzumab deruxtecan showed a 37% reduction in the risk of disease progression or death for patients with Her2-mutated NSCLC, achieving a median progression-free survival of 14.3 months. Additionally, Johnson & Johnson reported that Rybrevant combination therapy improved median overall survival to 34.3 months for patients with EGFR exon 20 insertion mutations. Research into HER2-targeted therapies also showed success in breast cancer, where Kelun-Biotech’s Disitamab Vedotin (SKB264) demonstrated a median progression-free survival of 11.1 months compared to 4.4 months for T-DM1. For small-cell lung cancer (SCLC), the TAISHAN-302 trial indicated that tambotatug pelitecan reduced the risk of death by 54% in relapsed patients compared to topotecan. Long-term data from the ADAURA trial further confirmed that adjuvant osimertinib provides sustained survival benefits for patients with resected, EGFR-mutated stage IB-IIIA NSCLC. ## Timeline ### 2026-09-14: HER2-targeted antibody-drug conjugates show positive Phase III trial results New Phase III clinical trials show significant improvements in progression-free survival for HER2-targeted antibody-drug conjugates in treating non-small cell lung cancer and breast cancer. 3 sources. https://clstr.news/cluster/her2-targeted-antibody-drug-conjugates-show-positive-phase-iii-trial-results ### 2026-09-14: Lung cancer clinical trials show significant survival improvements Major clinical trial updates presented at the WCLC 2026 show significant survival improvements for various lung cancer types using new targeted therapies like Rybrevant and trastuzumab deruxtecan. 10 sources. https://clstr.news/cluster/johnson-johnson-reports-survival-breakthrough-for-rybrevant-in-lung-cancer-study --- Cite as: Advancements in lung and breast cancer clinical trials. CLSTR, https://clstr.news/situations/advancements-in-lung-and-breast-cancer-clinical-trials